Lacertatherapeutics.com Website Review

Besides world‐clas* basic AAV vectorology and clinical trial expertise, our team brings novel insight into developing targeted Unmatched scientific expertise and depth in the development, production, and application of AAV vectors Besides world-clas* basic AAV vectorology and clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological disease treatments. Our AAV expertise and platforms allow us to offer early access to novel capsid variant identification and robust, scalable AAV vector Lacerta Thera*eutics is a clinical stage gene therapy company using a constellation of proprietary adeno-as*ociated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Thera*eutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Thera*eutics founders are unsurpas*ed in AAV gene therapy. In addition to world-clas* basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal We are actively seeking collaborative partnership and out-licensing opportunities providing potential partners with numerous advantages over current AAV vector platforms. Our AAV expertise and platforms allow us to offer early access to novel capsid variant identification and robust, scalable vector manufacturing. By engaging us at an early stage, Lacerta will ensure that the decisions regarding capsid variant derivation and the creation of critical raw production materials are developed effectively in support of the OneBac platform.